| Date | Form | Description | Docs | XBRL | Pages |
| 09/13/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
13 | |
| 06/24/96 | DEF 14A | Definitive proxy statements |
|
14 | |
| 06/19/96 | 10-C | Change of number of shares outstanding or change of issuer name |
|
2 | |
| 06/18/96 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
1 | |
| 06/18/96 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
2 | |
| 06/14/96 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 | |
| 06/13/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
14 | |
| 04/24/96 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 | |
| 04/22/96 | 8-K | Current report filing |
|
4 | |
| 03/14/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
12 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...